Biopharmaceuticals Contract Manufacturing Market Size (2024 - 2029)

The biopharmaceutical contract manufacturing market is experiencing significant growth, driven by the impact of the COVID-19 pandemic, which has accelerated demand and expanded capacity within the industry. This growth trajectory is supported by strategic partnerships and collaborations among market players, enhancing the production and distribution of biologics, vaccines, and other therapeutic products. Despite these positive trends, the market faces challenges such as stringent regulatory requirements and rising logistics costs, which could impede its expansion.

Home Market Analysis Healthcare Research Biotechnology Research Bioservices Research Contract Research and Manufacturing Services Research Biopharmaceutical Contract Manufacturing Market Market Size

Market Size of Biopharmaceuticals Contract Manufacturing Industry

Biopharmaceuticals Contract Manufacturing Market Summary
Study Period 2021 - 2029
Market Size (2024) USD 41.71 Billion
Market Size (2029) USD 79.19 Billion
CAGR (2024 - 2029) 13.68 %
Fastest Growing Market Asia-Pacific
Largest Market North America

Major Players

Biopharmaceuticals Contract Manufacturing Market Major Players

*Disclaimer: Major Players sorted in no particular order

Biopharmaceutical Contract Manufacturing Market Analysis

The Biopharmaceuticals Contract Manufacturing Market size is estimated at USD 41.71 billion in 2024, and is expected to reach USD 79.19 billion by 2029, growing at a CAGR of 13.68% during the forecast period (2024-2029).

The COVID-19 pandemic had a significant impact on the biopharmaceuticals contract manufacturing market. Contracts related to the COVID-19 pandemic immensely benefited the contract development and manufacturing organization (CDMO) industry. According to an article in Contract Pharma, dated February 2022, the COVID-19 pandemic took two years of tremendous work from the world's biopharmaceutical CMO. The industry's resilience is demonstrated by the astonishing speed with which it overcame the obstacles. The article also stated that revenues at biopharmaceutical CDMOs increased for recombinant proteins, vaccines, monoclonal antibodies, and mainstream biologics by an average of 29%. In fact, some have reported a growth of up to 40%-80% in revenue between 2020 and 2021. In addition, according to an article published in June 2021 in BioProcess International, the increases in CMO capacity spurred by the pandemic are anticipated to benefit the entire industry, especially for the production of cell and gene therapies. The COVID-19 pandemic boosted an already upward-trending biopharmaceutical CMO category. The long-term baseline growth pattern is expected to continue.

Furthermore, several biopharmaceutical CMOs offer services from drug production to drug manufacturing for other organizations in the case of proteins/peptides, antibodies, vaccines, and other biological substances. For instance, in March 2022, Bharat Biotech partnered with the Spanish biopharmaceutical firm, Biofabri, to develop, manufacture, and market a new tuberculosis vaccine. The new TB vaccine, 'MTBVAC,' is being manufactured and developed by Biofabri in close collaboration with the University of Zaragoza, the International AIDS Vaccine Initiative (IAVI), and the Tuberculosis Vaccine Initiative (TBVI). In September 2021, Baxter BioPharma Solutions, a CMO specializing in parenteral (injectable) pharmaceuticals, agreed to provide sterile manufacturing services for NVX-CoV2373, Novavax's COVID-19 recombinant nanoparticle vaccine candidate with Matrix-M adjuvant. The agreement is expected to advance commercial-scale manufacturing essential for the vaccine's production and distribution in the UK and European markets. Such activities by the market players are expected to boost the growth of the vaccine contract manufacturing market during the study period.

Moreover, strategic initiatives by the market players, such as contract manufacturing partnerships, are expected to boost the growth of the market studied. For instance, in April 2022, ChimeronBio announced that it had signed a manufacturing agreement with FUJIFILM DiosynthBiotechnologies (FDB) to advance its oncology portfolio to include clinics. ChimeronBio opted for FUJIFILM DiosynthBiotechnologies as its partner for transferring and scaling its drug substance manufacturing process.

However, stringent regulatory requirements and increasing logistics costs are factors hindering the growth of the market studied.

Biopharmaceutical Contract Manufacturing Industry Segmentation

As per the scope of the report, a contract manufacturing organization (CMO) is a company that serves other companies in the biopharmaceutical industry on a contract basis to provide comprehensive services from drug development to drug manufacturing. The biopharmaceuticals contract manufacturing market is segmented by product type and geography. By product type, the market is segmented into peptides/proteins, antibodies, vaccines, biosimilars, and other product types. By geography, the report examines the biopharmaceuticals contract manufacturing market in North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The report offers the market size and forecasts in terms of value in USD million for the above segments.

Product Type
Peptides/Proteins
Antibodies
Vaccines
Biosimilars
Other Product Types
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Biopharmaceuticals Contract Manufacturing Market Size Summary

The biopharmaceutical contract manufacturing market is poised for substantial growth, driven by the increasing demand for biologics and the strategic initiatives undertaken by key industry players. The market has shown resilience and adaptability, particularly in the wake of the COVID-19 pandemic, which significantly boosted the demand for contract development and manufacturing organizations (CDMOs). The pandemic highlighted the potential of vaccine manufacturing and outsourcing as a sustainable revenue stream, encouraging partnerships and collaborations to enhance production capabilities. Companies like Bharat Biotech and Baxter BioPharma Solutions have engaged in strategic agreements to advance vaccine development and manufacturing, underscoring the market's dynamic nature. The vaccine segment, in particular, is expected to maintain a significant market share, supported by advancements in monoclonal antibody therapy and ongoing government and health organization initiatives to expand vaccination efforts globally.

North America, with the United States at its forefront, is anticipated to hold a major share of the biopharmaceutical contract manufacturing market due to the presence of numerous biopharmaceutical companies and the high consumption of biologics. The region's growth is further bolstered by strategic mergers, partnerships, and investments in manufacturing capabilities, as seen with companies like Baxter International Inc. and Recipharm AB. The market is characterized by a consolidated landscape, with major players such as Boehringer Ingelheim GmbH, Lonza, and Samsung BioLogics dominating the scene. These companies are actively involved in expanding their manufacturing capacities and enhancing their service offerings to meet the rising demand for biologics and vaccines. As the need for biological drugs continues to rise, driven by the increasing burden of chronic diseases, the contract manufacturing market is expected to witness significant growth over the forecast period.

Explore More

Biopharmaceuticals Contract Manufacturing Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Increasing Outsourcing by Biopharmaceutical Firms

      2. 1.2.2 Increasing Investments in Research and Development

      3. 1.2.3 Expansion in the Service Offering of CMOs

    3. 1.3 Market Restraints

      1. 1.3.1 Stringent Regulatory Requirements

      2. 1.3.2 Increasing Logistics Costs

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 2.1 Product Type

      1. 2.1.1 Peptides/Proteins

      2. 2.1.2 Antibodies

      3. 2.1.3 Vaccines

      4. 2.1.4 Biosimilars

      5. 2.1.5 Other Product Types

    2. 2.2 Geography

      1. 2.2.1 North America

        1. 2.2.1.1 United States

        2. 2.2.1.2 Canada

        3. 2.2.1.3 Mexico

      2. 2.2.2 Europe

        1. 2.2.2.1 Germany

        2. 2.2.2.2 United Kingdom

        3. 2.2.2.3 France

        4. 2.2.2.4 Italy

        5. 2.2.2.5 Spain

        6. 2.2.2.6 Rest of Europe

      3. 2.2.3 Asia-Pacific

        1. 2.2.3.1 China

        2. 2.2.3.2 Japan

        3. 2.2.3.3 India

        4. 2.2.3.4 Australia

        5. 2.2.3.5 South Korea

        6. 2.2.3.6 Rest of Asia-Pacific

      4. 2.2.4 Middle East and Africa

        1. 2.2.4.1 GCC

        2. 2.2.4.2 South Africa

        3. 2.2.4.3 Rest of Middle East and Africa

      5. 2.2.5 South America

        1. 2.2.5.1 Brazil

        2. 2.2.5.2 Argentina

        3. 2.2.5.3 Rest of South America

Biopharmaceuticals Contract Manufacturing Market Size FAQs

The Biopharmaceuticals Contract Manufacturing Market size is expected to reach USD 41.71 billion in 2024 and grow at a CAGR of 13.68% to reach USD 79.19 billion by 2029.

In 2024, the Biopharmaceuticals Contract Manufacturing Market size is expected to reach USD 41.71 billion.

Biopharmaceutical Contract Manufacturing Market Report Snapshots

Biopharmaceutical Contract Manufacturing Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)